Companies · Other Health Care

Transenterix Inc.

MORRISVILLE · Other Health Care

Diligence memoA one-page analyst read on Transenterix Inc. — recommendation, valuation, rhythm, risks.
$209.9M
Total raised · real
8
Rounds
8.2×
Latest step-up
Top 3%
Sector rank · raised
Series D+
Latest stage · inferred · Tue Sep 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

Transenterix Inc. looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.01× the median modeled value of Series D+ Other Health Care companies in 2016–2018 (7 peers) — value vs value, same stage and era.
Dormant
  • Last raise 8.8 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

Transenterix Inc. is one of 5376 Other Health Care companies tracked from MORRISVILLE. By capital raised it ranks among the largest (ahead of 98% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
1
Investors (latest)
2017-09-12
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$1.3B$2.5B$3.8B$5.0BSeed · 2010-01-12 Raised $2.0M (real) Modeled valuation $50M (est)Seed2010Series A · 2010-06-15 Raised $5.0M (real) Modeled valuation $100M (est)Series A2010Series A · 2012-02-17 Raised $8.3M (real) Modeled valuation $168M (est)Series A2012Series A · 2013-03-22 Raised $3.0M (real) Modeled valuation $61M (est)Series A2013Series D+ · 2013-09-03 Raised $160M (real) Modeled valuation $3.7B (est)Series D+2013Series B · 2013-09-03 Raised $30M (real) Modeled valuation $669M (est)Series B2013Series D+ · 2016-09-14 Raised $116K (real) Modeled valuation $2.7M (est)Series D+2016Series D+ · 2017-09-12 Raised $950K (real) Modeled valuation $22M (est)Series D+2017+$5.0M+$8.3M+$3.0M+$160M+$30M+$116K+$950KCumulative $210M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$2.0M · 2010
Series A$5.0M · 2010
Series A extension$8.3M · 2012
Series A extension$3.0M · 2013
Series D+$160.4M · 2013no Series B / Series C on file
Bridge · Series D+-stage$30.2M · 2013smaller follow-on
Series D+ extension$116K · 2016
Series D+ extension$950K · 2017

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Series C — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$21.9M
Base estimate est.
$5.1M
Conservative case
$47.9M
Upside case
$7.9M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series D+a $100M–$400M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Seed · modeled $49.6M · 2010-01-122010Series A · modeled $100.5M · 2010-06-15Series A · modeled $167.8M · 2012-02-17Series A · modeled $61.0M · 2013-03-22Series D+ · modeled $3.7B · 2013-09-03Series B · modeled $668.6M · 2013-09-03Series D+ · modeled $2.7M · 2016-09-14Series D+ · modeled $21.9M · 2017-09-122017
Model inputs · modeled:benchmark-stage-stepup-v1
12%
Dilution assumption
Implied ownership sold in the financing.
80%
Survival probability
64% low · 88% high
1.23×/yr
Annual markup
1.38×/yr upside case
6.0 yr
Elapsed time used
8.8 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
13 mo
Avg between rounds
$27.4M/yr
Capital velocity
16.5 yr
On record since
2010
First round
8
Rounds on file
How it compares to the market

Benchmarked against 5376 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 86× above median
This company$209.9M
Sector median$2.4M
Latest round — vs other Series D+ rounds in sector (real $, this stage) 0.0× of median
This company$950K
Sector median$123.0M
Modeled value — vs sector median (estimate, all stages) 1.0× of median
This company$21.9M
Sector median$22.1M

Raised more than 98% of sector peers (real $). Modeled value above 50% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series D+) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #7 of 7.

This companyCohort peer
$10.0M$100.0M$1.0B$10.0B$100.0B$10.0M$100.0M$1.0BCapital raised (log)BNVC Group Holdings, Inc. · Series D+ Raised $535.6M · modeled $6.9B (est)Endologix Inc /De/ · Series D+ Raised $420.0M · modeled $4.8B (est)SYFS Intermediate Holdings, LLC · Series D+ Raised $185.5M · modeled $4.3B (est)Allied Integral United, Inc. · Series D+ Raised $164.1M · modeled $3.8B (est)OneOncology Parent Holdings, LLC · Series D+ Raised $103.0M · modeled $2.4B (est)Aeneas Parent Corp. · Series D+ Raised $298.3M · modeled $644.1M (est)Transenterix Inc. (this company) Raised $209.9M · modeled $21.9M (est)Transenterix Inc.
CompanyStageRaised · realValue · estvs peer med.
BNVC Group Holdings, Inc.Series D+$535.6M$6.9B1.84×
Endologix Inc /De/Series D+$420.0M$4.8B1.28×
SYFS Intermediate Holdings, LLCSeries D+$185.5M$4.3B1.13×
Allied Integral United, Inc.Series D+$164.1M$3.8B1.00×
OneOncology Parent Holdings, LLCSeries D+$103.0M$2.4B0.63×
Aeneas Parent Corp.Series D+$298.3M$644.1M0.17×
Transenterix Inc. this companySeries D+$209.9M$21.9M0.01×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$2.0M2010-01-12$10.0M$49.6M85%
Series A$5.0M2010-06-15$22.6M$100.5M85%
Series A$8.3M2012-02-17$37.8M$167.8M85%
Series A$3.0M2013-03-22$13.7M$61.0M85%
Series D+$160.4M2013-09-03$1.3B$3.7B85%
Series B$30.2M2013-09-03$167.7M$668.6M85%
Series D+$116K2016-09-14$964K$2.7M85%
Series D+$950K2017-09-12$7.9M$21.9M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$2.0M2010-01-12
    • First recorded raise — entered as Seed.
    • 5 investors on this round.
  2. Series A$5.0M2010-06-15
    • Came back fast: 5 mo vs the ~14 mo sector norm.
    • Round 2.5× larger than the prior — scaling up.
    • 20 investors on this round.
  3. Series A$8.3M2012-02-17
    • Raised 20 mo later, in step with the ~14 mo sector norm.
    • Round 1.7× larger than the prior — scaling up.
    • 36 investors on this round.
  4. Series A$3.0M2013-03-22
    • Raised 13 mo later, in step with the ~14 mo sector norm.
    • Round 2.8× smaller than the prior — bridge or down round.
    • Revenue band moved No revenue → $0–$1M.
    • 17 investors on this round.
  5. Series D+$160.4M2013-09-03
    • Came back fast: 5 mo vs the ~14 mo sector norm.
    • Round 53.0× larger than the prior — scaling up.
    • 43 investors on this round.
  6. Series B$30.2M2013-09-03
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 5.3× smaller than the prior — bridge or down round.
    • 19 investors on this round.
  7. Series D+$116K2016-09-14
    • Raised again after 36 mo — slower than the ~14 mo sector norm.
    • Round 260.9× smaller than the prior — bridge or down round.
    • Switched to Rule 506(b) (was Rule 06).
    • 1 investor on this round.
  8. Series D+$950K2017-09-12
    • Raised 12 mo later, in step with the ~14 mo sector norm.
    • Round 8.2× larger than the prior — scaling up.
    • 1 investor on this round.
Intelligence
2018 ~Q4
Modeled next raise · ~13mo cadence
$2.9M
Modeled next size est.range $1.9M$4.6M
8.2×
Last step-up
$27.4M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Steven D. Rubin8 other2010-01
JANE H HSIAO4 other2010-01
Richard C. Pfenniger, Jr.3 other2010-01
PAUL A. LAVIOLETTE2 other2013-09
Todd M. Pope2 other2013-09
William N. Starling, Jr.2 other2013-09
David B. Milne1 other2013-09
James J. Martin1 other2012-02
Jeffrey G. Spragens1 other2010-01
Joseph P Slattery1 other2016-09
William N Kelley1 other2016-09
Adam S. Jackson2010-01
Aftab H. Kherani, M.D.2013-09
Aftab R Kherani2016-09
Andrea M Biffi2016-09
Anthony N Fernando2016-09
Chao C. Chen2010-01
Charles J. Filipi2010-01
Charles J. Filipi, M.D.2013-09
Dennis H. Dougherty2013-09
Jane H. Hsiao, Ph.D.2013-09
Kevin D. Wayne2010-01
Kevin T. Wayne2010-06
Phillip H. Frost, M.D.2013-09
Registry & provenance

Transenterix Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
876378
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Opko Health, Inc.PharmaceuticalsSeries D+$206.0M$6.2Bnetwork3 shared operators · same stage
Non Invasive Monitoring Systems Inc /Fl/Other Health CarePre-Seed$501K$15.4Mnetwork3 shared operators · same sector
Well Dot, Inc.Other Health CareSeries C$122.8M$1.2Bnetwork1 shared operator · same sector
SAB Biotherapeutics, Inc.BiotechnologySeries D+$182.5M$1.4Bnetwork1 shared operator · same stage
Transenterix IncOther Health CareSeries C$72.2M$45.7Mnetwork1 shared operator · same sector
Fluent, Inc.OtherSeries D+$264.9M$97.2Mnetwork1 shared operator · same stage
Cocrystal Pharma, Inc.PharmaceuticalsSeries A$28.9M$92.9Mnetwork2 shared operators
PROLOR Biotech, Inc.BiotechnologySeries B$26.4M$968.4Mnetwork2 shared operators
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
TranspareRx CorpOther Health CareSeed$20.3M90%
Transcarent, Inc.Other Health CareGrowth/Late$5.0B87%
TransCanna Holdings Inc.Other Health CarePre-Seed$13.3M85%
ProPedix, Inc.Other Health CarePre-Seed$2.8M84%
RenovoRx, Inc.Other Health CareSeries A$58.0M84%
Ocugenix CorpOther Health CareSeed$20.4M84%
RxAnte, Inc.Other Health CareSeries A$199.5M84%
Noninvasix, Inc.Other Health CareSeed$97.9M84%
Frequently asked
How much funding has Transenterix Inc. raised?
Transenterix Inc. has raised approximately $209.9M in disclosed capital across 8 recorded financing rounds, aggregated from public filings.
What is Transenterix Inc.'s estimated valuation?
Provath's modeled valuation for Transenterix Inc. is approximately $21.9M (modeled range $5.1M–$47.9M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Transenterix Inc. at?
Transenterix Inc.'s latest modeled financing stage is Series D+. Its most recent recorded round closed around Tue Sep 12.
What does Transenterix Inc. do and where is it based?
Transenterix Inc. operates in the Other Health Care sector, based in MORRISVILLE.
Explore related

See where Transenterix Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Transenterix Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.